Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom DOI Creative Commons

Elizabeta Knezović,

Marija Hefer,

Suzana Blažanović

et al.

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(3), P. 154 - 154

Published: Feb. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic steatohepatitis (MASH), represent a growing global health problem linked to obesity, insulin resistance, dyslipidemia. MASLD often leads fibrosis, cirrhosis, hepatocellular carcinoma. Currently, therapeutic options are limited, emphasizing the need for novel, targeted pharmacological interventions. Resmetirom, selective thyroid hormone receptor beta (THR-β) agonist, offers promising approach by specifically enhancing hepatic metabolism while minimizing systemic effects. Clinical trials have demonstrated capacity reduce triglyceride accumulation improve lipid profiles. Early- advanced-phase studies, including MAESTRO program, highlight significant reductions in fat content favorable impacts on noninvasive biomarkers of fibrosis with minimal side This review highlights evidence from pivotal explores resmetirom's mechanism action, compares efficacy safety other emerging agents. While resmetirom marks breakthrough non-cirrhotic MASH management, further long-term studies essential fully evaluate clinical benefits potential regulatory approval broader use MASH.

Language: Английский

Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur DOI
Stergios A. Pοlyzos,

Christos S. Mantzoros

Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 156253 - 156253

Published: March 1, 2025

Language: Английский

Citations

1
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom DOI Creative Commons

Elizabeta Knezović,

Marija Hefer,

Suzana Blažanović

et al.

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(3), P. 154 - 154

Published: Feb. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic steatohepatitis (MASH), represent a growing global health problem linked to obesity, insulin resistance, dyslipidemia. MASLD often leads fibrosis, cirrhosis, hepatocellular carcinoma. Currently, therapeutic options are limited, emphasizing the need for novel, targeted pharmacological interventions. Resmetirom, selective thyroid hormone receptor beta (THR-β) agonist, offers promising approach by specifically enhancing hepatic metabolism while minimizing systemic effects. Clinical trials have demonstrated capacity reduce triglyceride accumulation improve lipid profiles. Early- advanced-phase studies, including MAESTRO program, highlight significant reductions in fat content favorable impacts on noninvasive biomarkers of fibrosis with minimal side This review highlights evidence from pivotal explores resmetirom's mechanism action, compares efficacy safety other emerging agents. While resmetirom marks breakthrough non-cirrhotic MASH management, further long-term studies essential fully evaluate clinical benefits potential regulatory approval broader use MASH.

Language: Английский

Citations

0